EUVIMEDEUVIMED entdecken
Crossref

Formosanin C inhibits triple-negative breast cancer progression by suppressing the phosphorylation of STAT3 and the polarization of M2 macrophages

Yin-Wei Dai, Zhi-Xuan Wu, Yao Cheng, Hao-Dong Wu, Jia-Wei Chen, Lin-Xi Lv, Zi-Qiong Wang, Hong-Feng Li, Cong-Zhi Yan, Jing-Xia Bao, Cong-Hui Liu, Xuan-Xuan Dai

Breast Cancer Research and Treatment · 2025

DOI: 10.1007/s10549-025-07623-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von Yin-Wei Dai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated H…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, STAT3 Transcription Factor, Macrophages, Diosgenin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: the Zhejiang Medical Health Science and technology Program, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, the Competitive Research Project of Quzhou Science & Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Triple-negative breast cancer (TNBC), is a highly aggressive tumor. Formosanin C (FC) is a diosgenin with immunomodulatory and antitumor properties, the precise mechanism through which it is against TNBC remains uncertain. OBJECTIVE: Clarifying the mechanism of FC against TNBC. MATERIALS AND METHODS: The impact of FC on two TNBC cell lines for 24 h was investigated through various techniques including the CCK8 assay, flow cytometry, transwell assay, scratch tests, immunoblot assay, and immunofluorescence. To elucidate the mechanism behind the anti-TNBC effect of FC, MDA-MB-231 cells were subjected to STAT3 overexpression. Moreover, the in vivo efficacy of FC was examined using a xenograft nude mice (BALB/C). Mice were divided into the control group (equal amount of PBS), the napabucasin group (5 mg/kg) and the FC groups (1 mg/kg, 2 mg/kg). The study duration was 30 days. RESULTS: FC exhibited inhibitory effects against MDA-MB-231 and Hs578T cells. FC can decrease the migratory capacity of TNBC cells by inhibiting epithelial-mesenchymal transition (EMT). Meanwhile, we demonstrated that the inhibition of phosphorylation of STAT3 (Y705) is the crucial mechanism of FC against TNBC. Moreover, FC also hindered the polarization of macrophage M2. DISCUSSION AND CONCLUSION: This study is the first to show that FC restrains the EMT of TNBC cells by obstructing the STAT3 pathway and hinders the M2 polarization of macrophages and immune evasion. Therefore, FC holds the possibility of being utilized as a therapeutic remedy for TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsSTAT3 Transcription FactorMacrophagesDiosgeninHumansAnimalsFemaleMicePhosphorylationXenograft Model Antitumor AssaysCell Line, TumorEpithelial-Mesenchymal TransitionCell MovementDisease ProgressionMice, NudeCell ProliferationMice, Inbred BALB C

Stichwörter der Autor:innen

Epithelial-mesenchymal transitionNetwork pharmacologySingle-cell sequencing

Substanzen

STAT3 Transcription FactorSTAT3 protein, humanDiosgenin

Autor:innen und Institutionen

  • Department of Breast Surgery, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Breast Surgery, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. daosh…
  • Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. daoshidaixuanxuan@126.com.

Förderung

  • the Zhejiang Medical Health Science and technology Program
  • Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province
  • the Competitive Research Project of Quzhou Science & Technology Bureau
  • Wenzhou Science and Technology Planning Project

Zitieren

APA

Dai, Y. W., Wu, Z. X., Cheng, Y., Wu, H. D., Chen, J. W., Lv, L. X., Wang, Z. Q., Li, H. F., Yan, C. Z., Bao, J. X., Liu, C. H., & Dai, X. X. (2025). Formosanin C inhibits triple-negative breast cancer progression by suppressing the phosphorylation of STAT3 and the polarization of M2 macrophages. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-025-07623-8

Vancouver

Dai YW, Wu ZX, Cheng Y, Wu HD, Chen JW, Lv LX, et al. Formosanin C inhibits triple-negative breast cancer progression by suppressing the phosphorylation of STAT3 and the polarization of M2 macrophages. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-025-07623-8

BibTeX
@article{Dai2025,
  author = {Dai, Yin-Wei and Wu, Zhi-Xuan and Cheng, Yao and Wu, Hao-Dong and Chen, Jia-Wei and Lv, Lin-Xi and Wang, Zi-Qiong and Li, Hong-Feng and Yan, Cong-Zhi and Bao, Jing-Xia and Liu, Cong-Hui and Dai, Xuan-Xuan},
  title = {Formosanin C inhibits triple-negative breast cancer progression by suppressing the phosphorylation of STAT3 and the polarization of M2 macrophages},
  journal = {Breast Cancer Research and Treatment},
  year = {2025},
  doi = {10.1007/s10549-025-07623-8}
}
Kostenlos starten →